Advertisement

Local Therapies

  • Rachel Grossmann
  • Zvi Ram
  • Michael A. Vogelbaum
  • E. Antonio Chiocca
  • Manfred Westphal
  • Jörg-Christian Tonn
  • Friedrich Kreth
  • Niklas Thon
Chapter

Abstract

Local therapies in the context of cranial tumor encompass the concept of local application or local delivery, respectively. Apart from surgical resection which is the most obvious form of local therapy, radiation is also targeted to the field of the tumor, the residual tumor, or the resection cavity but is dealt within the respective chapters as is the surgical aspect. Here the focus is on therapies which are applied at the time of surgery either into the resection cavity or into the surrounding tissue or are delivered by surgical means like catheters into tumor tissue without resection.

References

  1. 1.
    Aboody KS, Najbauer J, Danks MK (2008) Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15:739–752CrossRefPubMedGoogle Scholar
  2. 2.
    Akimoto J (2016) Photodynamic therapy for malignant brain tumors. Neurol Med Chir 56:151–157CrossRefGoogle Scholar
  3. 3.
    Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M (1993) p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 55:982–987CrossRefPubMedGoogle Scholar
  4. 4.
    Beck TJ, Kreth FW, Beyer W, Mehrkens JH, Obermeier A, Stepp H, Stummer W, Baumgartner R (2007) Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 39:386–393CrossRefPubMedGoogle Scholar
  5. 5.
    Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076–2080CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Brady ML, Raghavan R, Singh D, Anand PJ, Fleisher AS, Mata J, Broaddus WC, Olbricht WL (2014) In vivo performance of a microfabricated catheter for intraparenchymal delivery. J Neurosci Methods 229:76–83CrossRefPubMedGoogle Scholar
  7. 7.
    Brem H, Gabikian P (2001) Biodegradable polymer implants to treat brain tumors. J Control Release 74:63–67CrossRefPubMedGoogle Scholar
  8. 8.
    Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–1012CrossRefPubMedGoogle Scholar
  9. 9.
    Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10:958–966CrossRefPubMedGoogle Scholar
  10. 10.
    Chiocca EA, Rabkin SD (2014) Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295–300CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cline HE, Hynynen K, Watkins RD, Adams WJ, Schenck JF, Ettinger RH, Freund WR, Vetro JP, Jolesz FA (1995) Focused US system for MR imaging-guided tumor ablation. Radiology 194:731–737CrossRefPubMedGoogle Scholar
  12. 12.
    Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, Walbert T, Chu A, Das A, Diago OR, Gammon D, Gruber HE, Hanna M, Jolly DJ, Kasahara N, McCarthy D, Mitchell L, Ostertag D, Robbins JM, Rodriguez-Aguirre M, Vogelbaum MA (2016) Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med 8:341ra375CrossRefGoogle Scholar
  13. 13.
    Coluccia D, Fandino J, Schwyzer L, O’Gorman R, Remonda L, Anon J, Martin E, Werner B (2014) First noninvasive thermal ablation of a brain tumor with MR-guided focused ultrasound. J Ther Ultrasound 2:17CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Desjardins A, Gromeier M, Herndon JE II, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:150–161CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson M, Hoopes PJ (2003) Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperth 19:267–294CrossRefGoogle Scholar
  16. 16.
    Eigenbrod S, Trabold R, Brucker D, Eros C, Egensperger R, La Fougere C, Gobel W, Ruhm A, Kretzschmar HA, Tonn JC, Herms J, Giese A, Kreth FW (2014) Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochir 156:1427–1440CrossRefPubMedGoogle Scholar
  17. 17.
    Ferguson S, Lesniak MS (2007) Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv 4:169–180CrossRefPubMedGoogle Scholar
  18. 18.
    Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS (2008) Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5:123–127CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95:652–660CrossRefPubMedGoogle Scholar
  20. 20.
    Fujishiro T, Nonoguchi N, Pavliukov M, Ohmura N, Park Y, Kajimoto Y, Ishikawa T, Nakano I, Kuroiwa T (2018) 5-aminolevulinic acid-mediated photodynamic therapy can target human glioma stem-like cells refractory to antineoplastic agents. Photodiagn Photodyn Ther 24:58–68CrossRefGoogle Scholar
  21. 21.
    Gad SC (2014) Safety and regulatory requirements and challenge for CNS drug development. Neurobiol Dis 61:39–46CrossRefPubMedGoogle Scholar
  22. 22.
    Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ, Neumann JO, Schoning T, Husing J, Beelte B, Kiprianova I, Roscher M, Bhat R, von Deimling A, Bruck W, Just A, Frehtman V, Lobhard S, Terletskaia-Ladwig E, Fry J, Jochims K, Daniel V, Krebs O, Dahm M, Huber B, Unterberg A, Rommelaere J (2017) Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Mol Ther 25:2620–2634CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Lecluse Y, van Beusechem VW, Gerritsen WR, Kirn DH, Vassal G (2003) Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer 89:577–584CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Giese A, Bock HC, Kantelhardt SR, Rohde V (2010) Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cen Eur Neurosurg 71:199–206CrossRefGoogle Scholar
  25. 25.
    Goetz CM, Rachinger W, Decker M, Gildehaus FJ, Stocker S, Jung G, Tatsch K, Tonn JC, Reulen HJ (2005) Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats. Cancer Immunol Immunother 54:337–344CrossRefPubMedGoogle Scholar
  26. 26.
    Gutenberg A, Lumenta CB, Braunsdorf WE, Sabel M, Mehdorn HM, Westphal M, Giese A (2013) The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neuro-Oncol 113:163–174CrossRefGoogle Scholar
  27. 27.
    Harsh GR, Deisboeck TS, Louis DN, Hilton J, Colvin M, Silver JS, Qureshi NH, Kracher J, Finkelstein D, Chiocca EA, Hochberg FH (2000) Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 92:804–811CrossRefPubMedGoogle Scholar
  28. 28.
    Johansson A, Faber F, Kniebuhler G, Stepp H, Sroka R, Egensperger R, Beyer W, Kreth FW (2013) Protoporphyrin IX fluorescence and photobleaching during interstitial photodynamic therapy of malignant gliomas for early treatment prognosis. Lasers Surg Med 45:225–234CrossRefPubMedGoogle Scholar
  29. 29.
    Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549–556CrossRefPubMedGoogle Scholar
  30. 30.
    Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y (2007) Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 104:10152–10157CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kleinberg L (2016) Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy. Patient Prefer Adherence 10:2397–2406CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, Berger MS, Bankiewicz K (2005) Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103:923–929CrossRefPubMedGoogle Scholar
  33. 33.
    Kreth FW, Faist M, Grau S, Ostertag CB (2006) Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors. Cancer 106:1372–1381CrossRefPubMedGoogle Scholar
  34. 34.
    Kreth FW, Faist M, Rossner R, Birg W, Volk B, Ostertag CB (1997) The risk of interstitial radiotherapy of low-grade gliomas. Radiother Oncol 43:253–260CrossRefPubMedGoogle Scholar
  35. 35.
    Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB (1997) Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer 79:370–379CrossRefPubMedGoogle Scholar
  36. 36.
    Kreth FW, Faist M, Warnke PC, Rossner R, Volk B, Ostertag CB (1995) Interstitial radiosurgery of low-grade gliomas. J Neurosurg 82:418–429CrossRefPubMedGoogle Scholar
  37. 37.
    Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-Oncology 12:871–881CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837–844CrossRefPubMedGoogle Scholar
  39. 39.
    Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK (2003) Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21:2508–2518CrossRefPubMedGoogle Scholar
  40. 40.
    Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J (2018) Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol 36:1419–1427CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Larsson B (1992) Radiological fundamentals in radiosurgery. In: Steiner L (ed) Radiosurgery: baseline and trends. Raven, New York, pp 3–14Google Scholar
  42. 42.
    Lawler SE, Speranza MC, Cho CF, Chiocca EA (2017) Oncolytic viruses in cancer treatment: a review. JAMA Oncol 3:841–849CrossRefPubMedGoogle Scholar
  43. 43.
    Liberman B, Gianfelice D, Inbar Y, Beck A, Rabin T, Shabshin N, Chander G, Hengst S, Pfeffer R, Chechick A, Hanannel A, Dogadkin O, Catane R (2009) Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study. Ann Surg Oncol 16:140–146CrossRefPubMedGoogle Scholar
  44. 44.
    Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY (2009) Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17:199–207CrossRefPubMedGoogle Scholar
  45. 45.
    Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7:867–874CrossRefPubMedGoogle Scholar
  46. 46.
    Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, Fiveash JB, Gillespie GY (2014) A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 22:1048–1055CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Mathios D, Kim JE, Mangraviti A, Phallen J, Park CK, Jackson CM, Garzon-Muvdi T, Kim E, Theodros D, Polanczyk M, Martin AM, Suk I, Ye X, Tyler B, Bettegowda C, Brem H, Pardoll DM, Lim M (2016) Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med 8:370ra180CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    McDannold N, Clement GT, Black P, Jolesz F, Hynynen K (2010) Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery 66:323–332; discussion 332CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Mehrkens JH, Kreth FW, Muacevic A, Ostertag CB (2004) Long term course of WHO grade II astrocytomas of the Insula of Reil after I-125 interstitial irradiation. J Neurol 251:1455–1464CrossRefPubMedGoogle Scholar
  50. 50.
    Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Wembacher-Schroder E, Mittermeyer S, Westphal M, Sampson JH, Vogelbaum MA, Croteau D, Chang SM (2011) Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neuro-Oncol 101:267–277CrossRefGoogle Scholar
  51. 51.
    Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD (2018) Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res 24:266–275CrossRefPubMedGoogle Scholar
  52. 52.
    Mut M, Sherman JH, Shaffrey ME, Schiff D (2008) Cintredekin besudotox in treatment of malignant glioma. Expert Opin Biol Ther 8:805–812CrossRefPubMedGoogle Scholar
  53. 53.
    Peraud A, Goetz C, Siefert A, Tonn JC, Kreth FW (2007) Interstitial iodine-125 radiosurgery alone or in combination with microsurgery for pediatric patients with eloquently located low-grade glioma: a pilot study. Childs Nerv Syst 23:39–46CrossRefPubMedGoogle Scholar
  54. 54.
    Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173CrossRefGoogle Scholar
  55. 55.
    Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34:1933–1942CrossRefPubMedGoogle Scholar
  56. 56.
    Portnow J, Synold TW, Badie B, Tirughana R, Lacey SF, D’Apuzzo M, Metz MZ, Najbauer J, Bedell V, Vo T, Gutova M, Frankel P, Chen M, Aboody KS (2017) Neural stem cell-based anticancer gene therapy: a first-in-human study in recurrent high-grade glioma patients. Clin Cancer Res 23:2951–2960CrossRefPubMedGoogle Scholar
  57. 57.
    Ram Z, Cohen ZR, Harnof S, Tal S, Faibel M, Nass D, Maier SE, Hadani M, Mardor Y (2006) Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. Neurosurgery 59:949–955; discussion 955–946PubMedGoogle Scholar
  58. 58.
    Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE II, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397CrossRefPubMedGoogle Scholar
  59. 59.
    Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE II, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD (2008) A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology 10:182–189CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Reitz M, Demestre M, Sedlacik J, Meissner H, Fiehler J, Kim SU, Westphal M, Schmidt NO (2012) Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Transl Med 1:866–873CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Reulen HJ, Poepperl G, Goetz C, Gildehaus FJ, Schmidt M, Tatsch K, Pietsch T, Kraus T, Rachinger W (2015) Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy. J Neurosurg 123:760–770CrossRefPubMedGoogle Scholar
  62. 62.
    Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170:1109–1119 e1110CrossRefPubMedGoogle Scholar
  63. 63.
    Ruge MI, Simon T, Suchorska B, Lehrke R, Hamisch C, Koerber F, Maarouf M, Treuer H, Berthold F, Sturm V, Voges J (2011) Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome. J Clin Oncol 29:4151–4159CrossRefPubMedGoogle Scholar
  64. 64.
    Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE II, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology 10:320–329CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Sampson JH, Archer G, Pedain C, Wembacher-Schroder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodriguez-Ponce MI, Chang SM, Mittermeyer S, Croteau D, Puri RK (2010) Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 113:301–309CrossRefPubMedGoogle Scholar
  66. 66.
    Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA (2018) Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med 10:eaam7577CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Schnell O, Scholler K, Ruge M, Siefert A, Tonn JC, Kreth FW (2008) Surgical resection plus stereotactic 125I brachytherapy in adult patients with eloquently located supratentorial WHO grade II glioma—feasibility and outcome of a combined local treatment concept. J Neurol 255:1495–1502CrossRefPubMedGoogle Scholar
  68. 68.
    Sloan AE, Ahluwalia MS, Valerio-Pascua J, Manjila S, Torchia MG, Jones SE, Sunshine JL, Phillips M, Griswold MA, Clampitt M, Brewer C, Jochum J, McGraw MV, Diorio D, Ditz G, Barnett GH (2013) Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article. J Neurosurg 118:1202–1219CrossRefPubMedGoogle Scholar
  69. 69.
    Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, Larson SM, Dunkel IJ (2018) Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol 19:1040–1050CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Spiegel BM, Esrailian E, Laine L, Chamberlain MC (2007) Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 21:775–787CrossRefPubMedGoogle Scholar
  71. 71.
    Stepp H, Stummer W (2018) 5-ALA in the management of malignant glioma. Lasers Surg Med 50:399–419CrossRefPubMedGoogle Scholar
  72. 72.
    Stummer W, Beck T, Beyer W, Mehrkens JH, Obermeier A, Etminan N, Stepp H, Tonn JC, Baumgartner R, Herms J, Kreth FW (2008) Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. J Neuro-Oncol 87:103–109CrossRefGoogle Scholar
  73. 73.
    Stummer W, van den Bent MJ, Westphal M (2011) Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir 153:1211–1218CrossRefPubMedGoogle Scholar
  74. 74.
    Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192–2202CrossRefPubMedGoogle Scholar
  75. 75.
    Vecil GG, Lang FF (2003) Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neuro-Oncol 65:237–246CrossRefGoogle Scholar
  76. 76.
    Vogelbaum MA, Brewer C, Barnett GH, Mohammadi AM, Peereboom DM, Ahluwalia MS, Gao S (2018) First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. J Neurosurg 1–10Google Scholar
  77. 77.
    von Neubeck C, Seidlitz A, Kitzler HH, Beuthien-Baumann B, Krause M (2015) Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. Br J Radiol 88:20150354CrossRefGoogle Scholar
  78. 78.
    Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neuro-Oncol 64:125–137Google Scholar
  79. 79.
    Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5:79–88CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Westphal M, Yla-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R, Ram Z (2013) Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 14:823–833CrossRefPubMedGoogle Scholar
  81. 81.
    Wheeler LA, Manzanera AG, Bell SD, Cavaliere R, McGregor JM, Grecula JC, Newton HB, Lo SS, Badie B, Portnow J, Teh BS, Trask TW, Baskin DS, New PZ, Aguilar LK, Aguilar-Cordova E, Chiocca EA (2016) Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro-Oncology 18:1137–1145CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Rachel Grossmann
    • 1
  • Zvi Ram
    • 1
  • Michael A. Vogelbaum
    • 2
  • E. Antonio Chiocca
    • 3
  • Manfred Westphal
    • 4
  • Jörg-Christian Tonn
    • 5
  • Friedrich Kreth
    • 6
  • Niklas Thon
    • 6
  1. 1.Department of NeurosurgeryTel Aviv Sourasky Medical Center, TASMCTel AvivIsrael
  2. 2.Rose Ella Burkhardt Brain Tumor and NeuroOncology CenterCleveland Clinic Lerner College of Medicine of Case Western Reserve UniversityClevelandUSA
  3. 3.Department of NeurosurgeryBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  4. 4.Department of NeurosurgeryUniversity of Hamburg, University Hospital Eppendorf, HamburgHamburgGermany
  5. 5.Department of NeurosurgeryUniversity Hospital Ludwig Maximilian University MunichMunichGermany
  6. 6.Department of NeurosurgeryLMU, Campus GrosshadernMunichGermany

Personalised recommendations